Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 15/20 | 0.78 |
| ▸ | LCK | P06239 | 6/20 | 0.78 |
| ▸ | RET | P07949 | 3/20 | 0.76 |
| ▸ | GAK | O14976 | 1/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.76 |
| ▸ | STK10 | O94804 | 1/20 | 0.76 |
| ▸ | FLT3 | P36888 | 1/20 | 0.76 |
| ▸ | JAK3 | P52333 | 1/20 | 0.76 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.76 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.76 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.76 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.76 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.76 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.76 |
| ▸ | CLK1 | P49759 | 2/20 | 0.75 |
| ▸ | FBP1 | P09467 | 2/20 | 0.75 |
| ▸ | AURKA | O14965 | 1/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5473772 | 0.99 | KDR (0.97) | KDRFLT1EGFRLCKRET | |
| SCHEMBL8933814 | 0.94 | KDR (0.88) | KDRFLT1EGFRLCKRET | |
| Hydrochloric Acid SCHEMBL8808201 | 0.93 | KDR (0.86) | KDRFLT1EGFRLCKRET | |
| SCHEMBL31067633 | 0.91 | KDR (0.82) | KDRFLT1EGFRAURKAAURKB | |
| SCHEMBL5242610 | 0.90 | KDR (0.81) | KDRFLT1EGFRLCKRET | |
| SCHEMBL5239666 | 0.89 | KDR (0.80) | KDRFLT1EGFRLCKRET | |
| SCHEMBL5236221 | 0.89 | KDR (0.78) | KDRFLT1EGFRLCKRET | |
| SCHEMBL5467825 | 0.87 | EGFR (1.00) | KDRFLT1EGFRLCKRET | |
| SCHEMBL3533221 | 0.87 | EGFR (0.80) | KDRFLT1EGFRLCKRET | |
| SCHEMBL5473778 | 0.87 | EGFR (0.80) | KDRFLT1EGFRLCKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513267-B2 | 4-anilinoquinazoline derivatives with adenosine-kinase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2013-08-20 | — | — | US | disclosed |
| EP-1737832-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES WITH ADENOSINE-KINASE INHIBITORY PROPERTIES | UNICAMP (BR) | 2011-12-14 | — | — | EP | disclosed |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2007-03-15 | — | — | US | disclosed |
| US-6638939-B2 | Anticancer agents | PARKER HUGHES INSTITUTE | 2003-10-28 | — | — | US | disclosed |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2002-08-15 | — | — | US | disclosed |
| US-6358962-B2 | ANTIALLERGENS; ANTITUMOR AGENTS; ANTICANCER AGENTS | PARKER HUGHES INSTITUTE | 2002-03-19 | — | — | US | disclosed |
| EP-1162974-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | Parker Hughes Institute (US) | 2001-12-19 | — | — | EP | disclosed |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HUGHES INSTITUTE (US) | 2001-08-23 | — | — | US | disclosed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | disclosed |
| WO-2000056338-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | CMA1, MAST3, MAST1 | KDR 2810/4885FLT1 2293/4885EGFR 3336/4885 |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | ADK, AK1, ADORA3 | KDR 1289/4885FLT1 1551/4885EGFR 3142/4885 |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | KDR 3004/4885FLT1 3496/4885EGFR 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.